BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M, Retamozo S, Bové A, Bosch X, Sanchez-Tapias JM. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011;90:359-371. [PMID: 22033451 DOI: 10.1097/md.0b013e3182380a76] [Cited by in Crossref: 197] [Cited by in F6Publishing: 59] [Article Influence: 19.7] [Reference Citation Analysis]
Number Citing Articles
1 Woziwodzka A, Rybicka M, Sznarkowska A, Romanowski T, Dręczewski M, Stalke P, Bielawski KP. TNF-α polymorphisms affect persistence and progression of HBV infection. Mol Genet Genomic Med 2019;7:e00935. [PMID: 31441603 DOI: 10.1002/mgg3.935] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
2 Axiaris G, Zampeli E, Michopoulos S, Bamias G. Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment. World J Gastroenterol 2021; 27(25): 3762-3779 [PMID: 34321842 DOI: 10.3748/wjg.v27.i25.3762] [Reference Citation Analysis]
3 Kato M, Atsumi T. Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention. Rheumatol Int 2016;36:635-41. [PMID: 26573663 DOI: 10.1007/s00296-015-3395-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
4 Etzion O, Ghany MG. Screening for hepatitis B virus to prevent viral reactivation - who and when? Clinical Liver Disease. 2015;5:47-50. [PMID: 31040948 DOI: 10.1002/cld.458] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
5 Chiu YM, Lai MS, Chan KA. Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections. PLoS One 2018;13:e0196210. [PMID: 29694398 DOI: 10.1371/journal.pone.0196210] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Nard FD, Todoerti M, Grosso V, Monti S, Breda S, Rossi S, Montecucco C, Caporali R. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. World J Hepatol 2015; 7(3): 344-361 [PMID: 25848463 DOI: 10.4254/wjh.v7.i3.344] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
7 Chen YH, de Carvalho HM, Kalyoncu U, Llamado LJQ, Solano G, Pedersen R, Lukina G, Lichauco JJ, Vasilescu RS. Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice. Biologics 2018;12:1-9. [PMID: 29391775 DOI: 10.2147/BTT.S148606] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Felis-Giemza A, Olesińska M, Świerkocka K, Więsik-Szewczyk E, Haładyj E. Treatment of rheumatic diseases and hepatitis B virus coinfection. Rheumatol Int 2015;35:385-92. [PMID: 25549599 DOI: 10.1007/s00296-014-3195-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
9 Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol 2016; 22(28): 6444-6455 [PMID: 27605880 DOI: 10.3748/wjg.v22.i28.6444] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
10 Fiore M, Leone S, Maraolo AE, Berti E, Damiani G. Liver Illness and Psoriatic Patients. Biomed Res Int 2018;2018:3140983. [PMID: 29546055 DOI: 10.1155/2018/3140983] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
11 Pattullo V. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure. World J Hepatol 2015; 7(7): 954-967 [PMID: 25954478 DOI: 10.4254/wjh.v7.i7.954] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
12 Tavakolpour S, Alavian SM, Sali S. Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened. Hepat Mon 2016;16:e35810. [PMID: 27257429 DOI: 10.5812/hepatmon.35810] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
13 Harigai M, Mochida S, Mimura T, Koike T, Miyasaka N. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. Mod Rheumatol. [DOI: 10.1007/s10165-012-0810-y] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61:703-711. [PMID: 25412906 DOI: 10.1002/hep.27609] [Cited by in Crossref: 134] [Cited by in F6Publishing: 115] [Article Influence: 19.1] [Reference Citation Analysis]
15 Li Y, Li S, Duan X, Yang C, Xu M, Chen L. Macrophage Phenotypes and Hepatitis B Virus Infection. J Clin Transl Hepatol. 2020;8:424-431. [PMID: 33447526 DOI: 10.14218/jcth.2020.00046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
16 Taylor PC, Atzeni F, Balsa A, Gossec L, Müller-Ladner U, Pope J. The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. J Clin Med 2021;10:509. [PMID: 33535498 DOI: 10.3390/jcm10030509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Yamamoto-Furusho JK, Bosques-Padilla F, Daffra P, De Paula JA, Etchevers J, Galiano MT, Ibañez P, Juliao F, Kotze PG, Marroquín de la Garza JM, Monreal Robles R, Rocha JL, Steinwurz F, Vázquez-Frías R, Veitia G, Zaltman C. Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part). Rev Gastroenterol Mex 2017;82:134-55. [PMID: 28318706 DOI: 10.1016/j.rgmx.2016.07.005] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 2014;11:209-19. [PMID: 24247262 DOI: 10.1038/nrgastro.2013.216] [Cited by in Crossref: 155] [Cited by in F6Publishing: 137] [Article Influence: 17.2] [Reference Citation Analysis]
19 López-Serrano P, Briongos ELF, Alonso EC, Pérez-Calle JL, Rodríguez CF. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy. World J Hepatol 2015; 7(3): 539-547 [PMID: 25848477 DOI: 10.4254/wjh.v7.i3.539] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
20 Gonzalez SA, Perrillo RP. Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy. Clin Infect Dis. 2016;62 Suppl 4:S306-S313. [PMID: 27190320 DOI: 10.1093/cid/ciw043] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
21 Etzion O, Novack V, Perl Y, Abel O, Schwartz D, Munteanu D, Abufreha N, Ben-Yaakov G, Maoz ED, Moshaklo A, Dizingf V, Fich A. Sci-B-VacTM Vs ENGERIX-B Vaccines for Hepatitis B Virus in Patients with Inflammatory Bowel Diseases: A Randomised Controlled Trial. J Crohns Colitis. 2016;10:905-912. [PMID: 26928962 DOI: 10.1093/ecco-jcc/jjw046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
22 Park EJ, Kim H, Jung SM, Sung YK, Baek HJ, Lee J. The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus. Korean J Intern Med 2020;35:41-59. [PMID: 31935319 DOI: 10.3904/kjim.2019.411] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
23 Holmes JA, Yu ML, Chung RT. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals. Expert Opin Drug Saf. 2017;16:651-672. [PMID: 28471314 DOI: 10.1080/14740338.2017.1325869] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
24 Seto WK, Wong DK, Chan TS, Hwang YY, Fung J, Liu KS, Gill H, Lam YF, Cheung KS, Lie AK, Lai CL, Kwong YL, Yuen MF. Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy. Am J Gastroenterol. 2016;111:1788-1795. [PMID: 27644733 DOI: 10.1038/ajg.2016.436] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 7.7] [Reference Citation Analysis]
25 Seetharam A, Perrillo R, Gish R. Immunosuppression in Patients with Chronic Hepatitis B. Curr Hepatol Rep. 2014;13:235-244. [PMID: 25101233 DOI: 10.1007/s11901-014-0238-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
26 Naumann L, Feist E, Burmester GR. [Anticytokine therapy]. Internist (Berl) 2013;54:449-61; quiz 462-3. [PMID: 23463462 DOI: 10.1007/s00108-012-3202-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Visram A, Chan KK, McGee P, Boro J, Hicks LK, Feld JJ. Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening. PLoS One. 2015;10:e0120749. [PMID: 25875198 DOI: 10.1371/journal.pone.0120749] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
28 Lieber SR, Fried MW. Controversies in hepatitis C therapy: Reactivation of hepatitis B virus. Clin Liver Dis (Hoboken) 2017;10:87-92. [PMID: 31186893 DOI: 10.1002/cld.665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Coukos J, Farraye FA. Update on Vaccinating the Patient With Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2018;16:548-60. [PMID: 30293209 DOI: 10.1007/s11938-018-0200-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
30 Yuen MF. Need to improve awareness and management of hepatitis B reactivation in patients receiving immunosuppressive therapy. Hepatol Int 2016;10:102-5. [PMID: 26739134 DOI: 10.1007/s12072-015-9694-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
31 Schwaneck EC, Krone M, Kreissl-Kemmer S, Weißbrich B, Weiss J, Tony HP, Gadeholt O, Schmalzing M, Geier A. Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs-a single-center analysis of 2054 patients. Clin Rheumatol 2018;37:2963-70. [PMID: 30238380 DOI: 10.1007/s10067-018-4295-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
32 Lin TC, Yoshida K, Tedeschi SK, de Abreu MM, Hashemi N, Solomon DH. Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2018;70:724-731. [PMID: 28834412 DOI: 10.1002/acr.23346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
33 Kalyoncu U, Emmungil H, Onat AM, Yılmaz S, Kaşifoglu T, Akar S, İnanç N, Yıldız F, Küçükşahin O, Karadağ Ö, Mercan R, Bes C, Yazısız V, Yılmazer B, Özmen M, Erten Ş, Şenel S, Yazıcı A, Taşçılar K, Kalfa M, Kiraz S, Kısacık B, Pehlivan Y, Kılıç L, Şimşek İ, Çefle A, Akkoç N, Direskeneli H, Erken E, Turgay M, Öztürk MA, Soy M, Aksu K, Dinç A, Ertenli İ. Current antiviral practice and course of Hepatitis B virus infection in inflammatory arthritis: a multicentric observational study (A + HBV study). Eur J Rheumatol 2015;2:149-54. [PMID: 27708953 DOI: 10.5152/eurjrheum.2015.0111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
34 Pattullo V. Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol. 2016;22:219-237. [PMID: 27291888 DOI: 10.3350/cmh.2016.0024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 9.3] [Reference Citation Analysis]
35 Cantini F, Boccia S, Goletti D, Iannone F, Leoncini E, Panic N, Prignano F, Gaeta GB. HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. Int J Rheumatol 2014;2014:926836. [PMID: 25114684 DOI: 10.1155/2014/926836] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
36 Zhou Q, Zhang Q, Wang K, Huang T, Deng S, Wang Y, Cheng C. Anti-rheumatic Drug-induced Hepatitis B Virus Reactivation and Preventive Strategies for Hepatocellular Carcinoma. Pharmacol Res 2022;:106181. [PMID: 35301112 DOI: 10.1016/j.phrs.2022.106181] [Reference Citation Analysis]
37 Na M, Wang W, Fei Y, Josefsson E, Ali A, Jin T. Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice. PLoS One 2017;12:e0173492. [PMID: 28264025 DOI: 10.1371/journal.pone.0173492] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
38 Motolese A, Ceccarelli M, Macca L, Li Pomi F, Ingrasciotta Y, Nunnari G, Guarneri C. Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease. Biomedicines 2022;10:228. [DOI: 10.3390/biomedicines10020228] [Reference Citation Analysis]
39 Lopetuso LR, Mocci G, Marzo M, D'Aversa F, Rapaccini GL, Guidi L, Armuzzi A, Gasbarrini A, Papa A. Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver. Int J Mol Sci 2018;19:E2199. [PMID: 30060508 DOI: 10.3390/ijms19082199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
40 Manser CN, Maillard MH, Rogler G, Schreiner P, Rieder F, Bühler S; on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Vaccination in Patients with Inflammatory Bowel Diseases. Digestion 2020;101 Suppl 1:58-68. [PMID: 31968344 DOI: 10.1159/000503253] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
41 Onorato L, Pisaturo M, Camaioni C, Grimaldi P, Codella AV, Calò F, Coppola N. Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases. J Clin Med 2021;10:5201. [PMID: 34768721 DOI: 10.3390/jcm10215201] [Reference Citation Analysis]
42 Vilarrasa E, Puig L. Psoriasis: Biologic treatment and liver disease. World J Dermatol 2014; 3(4): 76-85 [DOI: 10.5314/wjd.v3.i4.76] [Cited by in CrossRef: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Abdulaziz S, Halabi H, Omair MA, Attar S, Alghamdi A, Shabrawishi M, Neyazi A, Alnazzawi H, Meraiani N, Almoallim H. Biological therapy in arthritis patients with hepatitis B or C infection: a multicenter retrospective case series. Eur J Rheumatol 2017;4:194-9. [PMID: 29164002 DOI: 10.5152/eurjrheum.2017.17003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
44 Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf. 2013;5:79-99. [PMID: 23569399 DOI: 10.2147/dhps.s28801] [Cited by in Crossref: 124] [Cited by in F6Publishing: 69] [Article Influence: 13.8] [Reference Citation Analysis]
45 Esposito S, Antoniol G, Labate M, Passadore L, Alvisi P, Daccò V, Ghizzi C, Colombo C, Principi N. Vaccines in Children with Inflammatory Bowel Disease: Brief Review. Vaccines (Basel) 2021;9:487. [PMID: 34064576 DOI: 10.3390/vaccines9050487] [Reference Citation Analysis]
46 Tzeng HT, Tsai HF, Chyuan IT, Liao HJ, Chen CJ, Chen PJ, Hsu PN. Tumor necrosis factor-alpha induced by hepatitis B virus core mediating the immune response for hepatitis B viral clearance in mice model. PLoS One. 2014;9:e103008. [PMID: 25047809 DOI: 10.1371/journal.pone.0103008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
47 Vassilopoulos D, Calabrese LH. Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV. Curr Rheumatol Rep. 2013;15:319. [PMID: 23436024 DOI: 10.1007/s11926-013-0319-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
48 Elbahrawy A, Alaboudy A, El Moghazy W, Elwassief A, Alashker A, Abdallah AM. Occult hepatitis B virus infection in Egypt. World J Hepatol 2015;7:1671-8. [PMID: 26140086 DOI: 10.4254/wjh.v7.i12.1671] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
49 Valaydon Z, Pellegrini M, Thompson A, Desmond P, Revill P, Ebert G. The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde. Clin Transl Immunology 2016;5:e115. [PMID: 28090316 DOI: 10.1038/cti.2016.68] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
50 Atteya A, Ahmad A, Daghstani D, Mushtaq K, Yassin MA. Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Cancer Control 2020;27:1073274820976594. [PMID: 33297765 DOI: 10.1177/1073274820976594] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
51 Nguyen GC, Devlin SM, Afif W, Bressler B, Gruchy SE, Kaplan GG, Oliveira L, Plamondon S, Seow CH, Williams C. Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol. 2014;28:275-285. [PMID: 24839622 DOI: 10.1155/2014/941245] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
52 Chyuan IT, Tsai HF, Tzeng HT, Sung CC, Wu CS, Chen PJ, Hsu PN. Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model. Cell Mol Immunol. 2015;12:317-325. [PMID: 25661729 DOI: 10.1038/cmi.2015.01] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
53 Ye H, Zhang XW, Mu R, Fang LK, Gu JR, Lin J, Du JF, Chen JW, Chen YJ, Wu LJ. Anti-TNF therapy in patients with HBV infection--analysis of 87 patients with inflammatory arthritis. Clin Rheumatol. 2014;33:119-123. [PMID: 24077913 DOI: 10.1007/s10067-013-2385-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
54 Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis. 2020;12:1759720X20912646. [PMID: 32206094 DOI: 10.1177/1759720x20912646] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
55 Huang W, Du L, Tang H. Hepatitis B virus reactivation: overview and management. Future Virology 2021;16:821-35. [DOI: 10.2217/fvl-2021-0275] [Reference Citation Analysis]
56 Arora A, Anand AC, Kumar A, Singh SP, Aggarwal R, Dhiman RK, Aggarwal S, Alam S, Bhaumik P, Dixit VK, Goel A, Goswami B, Kumar A, Kumar M, Madan K, Murugan N, Nagral A, Puri AS, Rao PN, Saraf N, Saraswat VA, Sehgal S, Sharma P, Shenoy KT, Wadhawan M; Members of the INASL taskforce on Hepatitis B. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids. J Clin Exp Hepatol 2018;8:403-31. [PMID: 30568345 DOI: 10.1016/j.jceh.2018.06.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
57 Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol 2015; 21(36): 10274-10289 [PMID: 26420955 DOI: 10.3748/wjg.v21.i36.10274] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 48] [Article Influence: 8.4] [Reference Citation Analysis]
58 Morisco F, Guarino M, La Bella S, Di Costanzo L, Caporaso N, Ayala F, Balato N. Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis. BMC Gastroenterol 2014;14:214. [PMID: 25523080 DOI: 10.1186/s12876-014-0214-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
59 Cannizzaro MV, Franceschini C, Esposito M, Bianchi L, Giunta A. Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management. Psoriasis (Auckl) 2017;7:35-40. [PMID: 29387606 DOI: 10.2147/PTT.S108209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
60 Kłujszo EH, Zarębska-Michaluk D, Kręcisz B, Witkowska A. Safety of therapies using ustekinumab in patients with psoriasis who have had hepatitis B virus infection. Dermatol Ther 2021;:e15274. [PMID: 34921578 DOI: 10.1111/dth.15274] [Reference Citation Analysis]
61 Jeong W, Choe J, Song B, Lee C, Cha H, Ghang B, Kim J. Effect of Low-Dose Corticosteroid Use on HBV Reactivation in HBsAg-positive Rheumatoid Arthritis Patients. TORJ 2021;15:39-44. [DOI: 10.2174/1874312902115010039] [Reference Citation Analysis]
62 Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology. 2017;152:1297-1309. [PMID: 28219691 DOI: 10.1053/j.gastro.2017.02.009] [Cited by in Crossref: 241] [Cited by in F6Publishing: 214] [Article Influence: 48.2] [Reference Citation Analysis]
63 Miyake Y, Hasebe A, Tanihira T, Shiraishi A, Imai Y, Tatsukawa H, Yamago H, Nakahara H, Shimizu Y, Ninomiya K, Hiraoka A, Miyata H, Ninomiya T, Michitaka K. Hepatitis B virus reactivation induced by infliximab administration in a patient with Crohn's disease. Case Reports Hepatol 2013;2013:461879. [PMID: 25374717 DOI: 10.1155/2013/461879] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
64 Canzoni M, Marignani M, Sorgi ML, Begini P, Biondo MI, Caporuscio S, Colonna V, Casa FD, Conigliaro P, Marrese C, Celletti E, Modesto I, Peragallo MS, Laganà B, Picchianti-Diamanti A, Rosa RD, Ferlito C, Salemi S, D'Amelio R, Stroffolini T. Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy. Microorganisms 2020;8:E1792. [PMID: 33207663 DOI: 10.3390/microorganisms8111792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
65 Reynolds JA, Manch RA, Gish RG. Medical interventions associated with HBV reactivation: Common and less common. Clinical Liver Disease. 2015;5:32-34. [PMID: 31040944 DOI: 10.1002/cld.413] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
66 Seto WK. Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. World J Hepatol 2015; 7(6): 825-830 [PMID: 25937860 DOI: 10.4254/wjh.v7.i6.825] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
67 Stasko SA, Hardin BJ, Smith JD, Moylan JS, Reid MB. TNF signals via neuronal-type nitric oxide synthase and reactive oxygen species to depress specific force of skeletal muscle. J Appl Physiol (1985) 2013;114:1629-36. [PMID: 23558387 DOI: 10.1152/japplphysiol.00871.2012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]